Jason Werner
Directeur des opérations chez ALIMERA SCIENCES, INC.
Fortune : 686 250 $ au 31/05/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Richard Eiswirth | M | 55 | 19 ans | |
Gerald W. St. Peter | M | 57 |
Eyevance Pharmaceuticals LLC
Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX.
Eyevance Pharmaceuticals Holdings, Inc.
Eyevance Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals Holdings, Inc operates as a holding company through its subsidiaries develops ophthalmic therapies for the ocular surface and anterior segment. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Fort Worth, TX. | 7 ans |
Charles Myers | M | 70 | 21 ans | |
Adam Morgan | M | 45 | 1 ans | |
David Holland | M | 60 | 21 ans | |
Erin Parsons | F | 48 | 3 ans | |
Michael Kaseta | M | 48 | 1 ans | |
Philip Ashman | M | 59 | 11 ans | |
Brian Levy | M | 72 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
John Snisarenko | M | 61 | 5 ans | |
Christopher S. Visick | M | - | 6 ans | |
Colin Richard Green | M | 80 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Peter Pizzo | M | 57 | 14 ans | |
David Alan Pool | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Phil Rosenfeld | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
David Boyer | M | - |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Jodi Luchs | M | - |
Eyevance Pharmaceuticals LLC
Eyevance Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Eyevance Pharmaceuticals LLC operates as a pharmaceutical company. It develops and commercializes ophthalmic products that enable optimal vision for the patients. The company was founded by Jerry St. Peter and Jason Werner in September 2017 and is headquartered in Forth Worth, TX. | 7 ans |
Richard Rubino | M | 66 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Margaret Pax | F | 64 | 1 ans | |
Elliot Maltz | M | 39 | - | |
David Dyer | M | - | 3 ans | |
Rajiv Sarman Shukla | M | 49 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | 5 ans |
James Blair | M | 84 |
InflammX Therapeutics, Inc.
InflammX Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy. | - |
Laura Cegala | F | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Russell Skibsted | M | 65 | 1 ans | |
Garheng Kong | M | 49 | 11 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Etats-Unis | 26 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jason Werner
- Réseau Personnel